Nova Eye Medical reported sales growth in its glaucoma segment for FY24, driven by strong performance in the US market.

Total segment revenue reached US$15.3 million ($23.5 million), up 37% year-over-year.

US sales contributed US$11.4 million ($17.5 million), marking a 73% increase from the previous year, driven by strong adoption of iTrack Advance.

The company's strategic investments in US field sales specialists have expanded geographic coverage and bolstered sales.

Nova Eye plans to further its growth strategy in markets including Canada, Western Europe, and Asia.